BofA raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $83 from $81 and keeps a Buy rating on the shares after the company reported positive topline results from a Phase 3 study of zilganersen in patients with Alexander disease. The news is “an incremental positive” as Ionis could add another product to its expanding commercial portfolio and the data further validates the company’s CNS platform technology, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals price target raised to $92 from $90 at Guggenheim
- Buy Rating for Ionis Pharmaceuticals: Promising Phase 3 Results for Zilganersen in Alexander Disease
- Buy Rating Affirmed for Ionis Pharmaceuticals Amid Promising Phase III Results for Zilganersen in Treating Alexander Disease
- Morning Movers: Metsera surges, Pfizer gains after acquisition pact
- Ionis Pharmaceuticals price target raised to $75 from $68 at Raymond James